Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone in type 2 diabetes mellitus (combination with sulfonylurea)
NCT00432679Phase 3Completed
- Sponsor
- GSK
- Start
- May 2006
- Primary completion
- Mar 2007
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Rosiglitazone + SU with Placebo + SU (2 arms). Primary endpoint: Glycosylated Hemoglobin at 16 weeks. Started May 2006; status: completed.
02
Drugs
rosiglitazone
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00432679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00432679.